# Tegoprubart PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/tegoprubart

> The next catalyst for tegoprubart, sponsored by Eledon Pharmaceuticals, Inc. (ELDN), is its primary completion, March 2029.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, half-year only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | tegoprubart |
| Codes | AT-1501 |
| Sponsor | Eledon Pharmaceuticals, Inc. (ELDN) https://sec-api.dev/companies/eldn/catalysts |
| Indications | [Kidney Transplant Rejection](https://sec-api.dev/indications/kidney-transplant-rejection) |
| Modality |  |
| FDA designations | fast track, orphan |

## Timeline

### May 2022: topline data readout

- Status: completed, positive. Date confidence: month. Stage: 2.
- First seen 2024-11-12, last confirmed 2025-11-14.
- SEC Form 10-Q (accession 0001193125-25-283275): "In May 2022, we completed the Phase 2a study and released positive topline results." https://www.sec.gov/Archives/edgar/data/1404281/000119312525283275/eldn-20250930.htm
- SEC Form 10-Q (accession 0001193125-25-180906): "In May 2022, we completed the Phase 2a study and released positive topline results." https://www.sec.gov/Archives/edgar/data/1404281/000119312525180906/eldn-20250630.htm
- SEC Form 10-Q (accession 0000950170-25-071582): "In May 2022, we completed the Phase 2a study and released positive topline results." https://www.sec.gov/Archives/edgar/data/1404281/000095017025071582/eldn-20250331.htm
- SEC Form 10-K (accession 0000950170-25-042754): "In May 2022, we completed the Phase 2a study and released positive topline results." https://www.sec.gov/Archives/edgar/data/1404281/000095017025042754/eldn-20241231.htm
- SEC Form 10-Q (accession 0000950170-24-125622): "In May 2022, we completed the Phase 2a study and released positive topline results." https://www.sec.gov/Archives/edgar/data/1404281/000095017024125622/eldn-20240930.htm

### September 11, 2025: primary completion

- Status: completed. Date confidence: exact. Stage: 2. Indication: Kidney Transplant Rejection.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05983770 (Safety and Efficacy of Tegoprubart in Patients Undergoing Kidney Transplantation): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-09-11 (ACTUAL); Lead Sponsor Eledon Pharmaceuticals." https://clinicaltrials.gov/study/NCT05983770

### Nov 2025: topline data readout

- Status: scheduled. Date confidence: month. Stage: 2.
- First seen 2024-11-12, last confirmed 2025-08-14.
- SEC Form 10-Q (accession 0001193125-25-180906): "We expect the last patient to be dosed in September 2025 and anticipate presenting topline results from the BESTOW study in November 2025." https://www.sec.gov/Archives/edgar/data/1404281/000119312525180906/eldn-20250630.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-071370): "In addition, we remain on track to report topline results from the Phase 2 BESTOW trial in the fourth quarter of 2025, which we believe has the potential to demonstrate the superiority of tegoprubart over standard of care, as measured by estimated glomerular filtration rate (eGFR)."" https://www.sec.gov/Archives/edgar/data/1404281/000095017025071370/eldn-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-042644): "Topline results from Phase 2 BESTOW trial of tegoprubart in kidney transplantation expected in fourth quarter of 2025" https://www.sec.gov/Archives/edgar/data/1404281/000095017025042644/eldn-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-24-125340): "Completed enrollment of Phase 2 BESTOW trial of tegoprubart in kidney transplantation four months ahead of schedule; on track to report topline results in fourth quarter of 2025" https://www.sec.gov/Archives/edgar/data/1404281/000095017024125340/eldn-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-25-180820): "Company on track to report topline results from Phase 2 BESTOW trial in kidney transplantation in November 2025" https://www.sec.gov/Archives/edgar/data/1404281/000119312525180820/eldn-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-103975): "Topline results from the Phase 2 BESTOW trial are anticipated in November 2025." https://www.sec.gov/Archives/edgar/data/1404281/000095017025103975/eldn-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-042644): "We are entering 2025 from a position of balance sheet strength and we are on track to deliver on multiple key milestones in the coming months, including topline results from our Phase 2 BESTOW trial in the fourth quarter of 2025."" https://www.sec.gov/Archives/edgar/data/1404281/000095017025042644/eldn-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-071370): "On track to report topline results from Phase 2 BESTOW trial in kidney transplantation in fourth quarter of 2025" https://www.sec.gov/Archives/edgar/data/1404281/000095017025071370/eldn-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-25-180820): ""With these encouraging results in hand, we look forward to sharing topline data later this year from our Phase 2 BESTOW trial in kidney transplantation and to continuing to explore tegoprubart's broad potential in other transplant indications."" https://www.sec.gov/Archives/edgar/data/1404281/000119312525180820/eldn-ex99_1.htm

### late 2026: trial start

- Status: scheduled. Date confidence: half. Stage: 3.
- First seen 2026-11-12, last confirmed 2026-11-12.
- Press release filed with the SEC (EX-99) (accession 0001193125-26-458378): ""We continue to execute across our key strategic priorities and make meaningful progress in the tegoprubart clinical program across multiple transplant types, including plans to initiate our global Phase 3 LEGACY trial in kidney transplantation by year end," said David-Alexandre C. Gros, M.D., Chief Executive Officer of Eledon." https://www.sec.gov/Archives/edgar/data/1404281/000119312526458378/eldn-ex99_1.htm

### March 2029: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Kidney Transplant Rejection.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07835581 (Study of Tegoprubart Efficacy and Safety Compared With Tacrolimus in Kidney Transplantation): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2029-03 (ESTIMATED); Lead Sponsor Eledon Pharmaceuticals." https://clinicaltrials.gov/study/NCT07835581

### Mar to Jun 2029: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Kidney Transplant Rejection.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07835581 (Study of Tegoprubart Efficacy and Safety Compared With Tacrolimus in Kidney Transplantation): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2029-03 (ESTIMATED); Lead Sponsor Eledon Pharmaceuticals." https://clinicaltrials.gov/study/NCT07835581

### December 2029: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Kidney Transplant Rejection.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06126380 (Long-Term Safety and Efficacy of Tegoprubart in Kidney Transplant Recipients): Overall Status ENROLLING_BY_INVITATION; Phase PHASE2; Primary Completion 2029-12 (ESTIMATED); Lead Sponsor Eledon Pharmaceuticals." https://clinicaltrials.gov/study/NCT06126380

### Dec 2029 to Mar 2030: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Kidney Transplant Rejection.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06126380 (Long-Term Safety and Efficacy of Tegoprubart in Kidney Transplant Recipients): Overall Status ENROLLING_BY_INVITATION; Phase PHASE2; Primary Completion 2029-12 (ESTIMATED); Lead Sponsor Eledon Pharmaceuticals." https://clinicaltrials.gov/study/NCT06126380

## Same indication

- [Frexalimab](https://sec-api.dev/pdufa/frexalimab) (SNY)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/tegoprubart.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Tegoprubart PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/tegoprubart

```bibtex
@misc{secapidev_pdufa_tegoprubart_20261116,
  title        = {Tegoprubart PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/tegoprubart}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_tegoprubart_20261116","title":"Tegoprubart PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/tegoprubart","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
